Eisai
Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Aricept | Donepezil | 1996-11-25 | 2025-2038 | |
| Banzel | Rufinamide | 2008-11-14 | ||
| Dayvigo | Lemborexant | 2020-04-07 | 2031-2035 | |
| Fycompa | Perampanel | 2012-07-23 | 2024-2026 | |
| Halaven | Eribulin | 2010-11-15 | 2023-2027 | |
| Hexalen | Altretamine | 1990-12-26 | ||
| Inovelon | Rufinamide | 2007-01-16 | ||
| Kisplyx | Lenvatinib | 2016-08-25 | 2025-2036 | |
| Lenvima | Lenvatinib | 2015-02-13 | 2025-2036 |
1
2
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
14
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use